Advaxis (NASDAQ:ADXS) Receives New Coverage from Analysts at StockNews.com
Investment analysts at StockNews.com initiated coverage on shares of Advaxis (NASDAQ:ADXS – Get Rating) in a research note issued on Monday. The firm set a “sell” rating on the stock. Advaxis Price Performance About Advaxis (Get Rating) Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) […]
Source: etfdailynews.com